162,812 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Empowered Funds LLC

Posted by Stanley Muller on Sep 2nd, 2026

Empowered Funds LLC bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 162,812 shares of the company’s stock, valued at approximately $3,286,000.

Other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its holdings in Amphastar Pharmaceuticals by 12.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock valued at $39,726,000 after acquiring an additional 228,262 shares during the period. TD Asset Management Inc grew its stake in shares of Amphastar Pharmaceuticals by 1.6% during the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock worth $52,571,000 after purchasing an additional 31,160 shares during the period. State Street Corp increased its holdings in shares of Amphastar Pharmaceuticals by 2.1% during the 4th quarter. State Street Corp now owns 1,531,786 shares of the company’s stock valued at $41,021,000 after purchasing an additional 31,044 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock valued at $37,344,000 after purchasing an additional 40,536 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Amphastar Pharmaceuticals by 41.6% during the 4th quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock valued at $33,134,000 after purchasing an additional 363,216 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on AMPH shares. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Zacks Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Six equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Amphastar Pharmaceuticals has a consensus rating of “Reduce” and a consensus price target of $22.50.

Get Our Latest Research Report on AMPH

Insider Activity

In other news, Director Richard K. Prins sold 7,973 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $20.30, for a total transaction of $161,851.90. Following the completion of the sale, the director owned 29,625 shares of the company’s stock, valued at $601,387.50. The trade was a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO William J. Peters sold 8,180 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $22.48, for a total transaction of $183,886.40. Following the transaction, the chief financial officer owned 172,846 shares of the company’s stock, valued at approximately $3,885,578.08. This trade represents a 4.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 29.60% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Trading Up 1.9%

Shares of NASDAQ:AMPH opened at $22.96 on Wednesday. The business’s 50 day moving average price is $20.37 and its 200-day moving average price is $20.65. Amphastar Pharmaceuticals, Inc. has a 1 year low of $16.65 and a 1 year high of $31.26. The firm has a market capitalization of $976.67 million, a price-to-earnings ratio of 13.59, a price-to-earnings-growth ratio of 4.34 and a beta of 0.89. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.40 and a quick ratio of 1.71.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.62 by $0.29. The company had revenue of $183.90 million during the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. On average, equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Profile

(Free Report)

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.